| Antiviral | EC50 ratio | Phenotype | Strain | Source | Marker | Assay | Reference |
|---|---|---|---|---|---|---|---|
| Ganciclovir | 6.50 | High level resistance | N/A | N/A | Recombinant | Details | Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients. (Feb 2007) |
| Cidofovir | 11.00 | High level resistance | N/A | N/A | Recombinant | Details | Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients. (Feb 2007) |
| Foscarnet | 0.80 | No resistance | N/A | N/A | Recombinant | Details | Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients. (Feb 2007) |
| Mutant | Resistances |
|---|---|
| D413del |
Brincidofovir:
|
|
Cidofovir:
|
|
|
Ganciclovir:
|
|
|
Foscarnet:
|
|
| D413E |
Ganciclovir:
|
|
Cidofovir:
|
|
|
Foscarnet:
|
|
| D413N |
Ganciclovir:
|
|
Cidofovir:
|
|
|
Foscarnet:
|
|
| D413Y |
Brincidofovir:
|
|
Cidofovir:
|
|
|
Ganciclovir:
|
|
|
Foscarnet:
|